Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study - Université de Franche-Comté Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2021

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study

Résumé

Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) of the isolates were resistant to both ceftazidime and imipenem.

Dates et versions

hal-04225901 , version 1 (03-10-2023)

Identifiants

Citer

Damien Fournier, Romain Carrière, Maxime Bour, Emilie Grisot, Pauline Triponney, et al.. Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study. Antimicrobial Agents and Chemotherapy, 2021, 65 (2), ⟨10.1128/AAC.01117-20⟩. ⟨hal-04225901⟩
2 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More